Clevidipine Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 0.5 mg/mL
Reference Brands: Cleviprex (USA)
Category:
Heart Disorder
Clevidipine is available in Injection
and strengths such as 0.5 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Clevidipine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Clevidipine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Clevidipine, marketed under the trade name Cleviprex, is an intravenous dihydropyridine calcium channel blocker indicated for the rapid reduction of blood pressure when oral therapy is not feasible or desirable. Administered exclusively via IV, clevidipine is titrated by healthcare practitioners to achieve precise blood pressure control. It has an ultra-short half-life of approximately one minute and is rapidly metabolized by blood and tissue esterases, allowing for immediate adjustment of antihypertensive effects.
Clevidipine selectively targets L-type calcium channels in vascular smooth muscle, with minimal effects on myocardial contractility or cardiac conduction. By dilating arterial vessels, it decreases systemic vascular resistance, effectively lowering mean arterial pressure without reducing cardiac filling pressure (preload). This selectivity ensures that myocardial oxygen demand is not increased and coronary blood flow remains stable, minimizing the risk of ischemia.
Due to its rapid onset, short duration, and high vascular selectivity, clevidipine is widely used in perioperative and critical care settings for the management of acute hypertension, hypertensive emergencies, and other situations requiring controlled and reversible blood pressure reduction.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing